Medicine & USMLE

Bortezomib, Carfilzomib

Oncology Pharm
  1. Bleomycin
  2. Dactinomycin, Actinomycin D
  3. Doxorubicin, Daunorubicin
  4. Azathioprine, 6-MP
  5. Cladribine
  6. Cytarabine
  7. Busulfan
  8. Cyclophosphamide, Ifosfamide
  9. Nitrosoureas
  10. Paclitaxel
  11. Vincristine, Vinblastine
  12. Cisplatin, Carboplatin, Oxaliplatin
  13. Etoposide, Teniposide
  14. Irinotecan, Topotecan
  15. Bevacizumab
  16. Erlotinib
  17. Cetuximab, Panitumumab
  18. Imatinib, Dasatinib
  19. Rituximab
  20. Bortezomib, Carfilzomib
  21. Trastuzumab
  22. Dabrafenib, Vemurafenib
  23. Raloxifene and Tamoxifen
  24. Hydroxyurea
  25. Procarbazine


Bortezomib and carfilzomib are proteasome inhibiting drugs that can induce arrest and apoptosis of cells at the G2-M phase of the cell cycle. These drugs have been shown to be particularly effective in the treatment of multiple myeloma and mantle cell lymphoma. Patients on bortezomib and carfilzomib may experience peripheral neuropathy or herpes zoster reactivation as side effects of their use. 

Key Points

  • Bortezomib, Carfilzomib
    • Mechanism
      • Proteasome inhibitors
        • Induce arrest at G2-M phase and apoptosis
    • Clinical use
      • Multiple myeloma
        • Proteasome inhibitors are thought to be particularly lethal to MM as MM synthesizes a ton of protein.
      • Mantle cell lymphoma
    • Adverse effects
      • Peripheral neuropathy
      • Herpes zoster reactivation